Skip to content
Menu

Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $20

Benzinga Newsdesk 5 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $17 to $20.

Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $17 to $20.

Read at benzinga.com

← All stock news